Stifel Financial’s C4 Therapeutics CCCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-10,438
Closed -$16.7K 3484
2025
Q1
$16.7K Sell
10,438
-2,923
-22% -$8.72K ﹤0.01% 3400
2024
Q4
$48.1K Sell
13,361
-15,054
-53% -$74.9K ﹤0.01% 3317
2024
Q3
$162K Sell
28,415
-662
-2% -$3.98K ﹤0.01% 3177
2024
Q2
$134K Buy
29,077
+9,065
+45% +$54.1K ﹤0.01% 3167
2024
Q1
$163K Buy
+20,012
New +$155K ﹤0.01% 3125

Other funds holding CCCC

Stifel Financial's CCCC Position: Q2 2025 in Review

Stifel Financial sold out of C4 Therapeutics (CCCC) in Q2 2025, closing a stake of 10,438 shares — an estimated $16.7K sold.

Stifel Financial first reported a position in CCCC in Q1 2024 and held it in 5 quarters. The position peaked at $163K in Q1 2024. 102 funds tracked by Wall St. Rank hold CCCC as of Q2 2025.

  • Stifel Financial reported no remaining C4 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Stifel Financial sold 10,438 C4 Therapeutics shares in Q2 2025, an estimated $16.7K.
  • Stifel Financial first reported a position in C4 Therapeutics in Q1 2024 and held it in 5 quarters.
  • Stifel Financial's C4 Therapeutics position peaked at $163K in Q1 2024.
  • 102 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2025.

Based on Stifel Financial's 13F filing for Q2 2025, filed 14 Aug 2025.